Outset Medical Appoints Andrea Saia to Board of Directors

Outset Medical Inc. has welcomed a new member to its Board of Directors.

The company is strengthening its consumer focus with the appointment of Andrea Saia to its governing body. Saia’s background in building iconic global brands will help Outset’s efforts to grow the home dialysis market and empower patients to take better charge of their health. A recognized global business leader, Saia is known for building world-class brands with innovative technologies that reshape industries and improve the health and well-being of consumers.

“Andrea’s extensive knowledge in both the medtech and consumer products spaces align with our vision to create a highly differentiated experience in the home for dialysis patients,” said Outset Medical CEO Leslie Trigg. “She brings a deep understanding of the consumer health landscape that will be invaluable as we expand our home dialysis footprint, and continue to invest in a rich, multi-faceted data ecosystem designed to empower dialysis patients.”
 
Saia currently serves on the board of Align Technology, a $40 billion medical technology company pioneering solutions for orthodontics and dentistry through manufacturing 3D digital scanners and the Invisalign clear aligners. She also is on the board of LivaNova PLC, a $4 billion global technology company creating breakthrough treatments for many conditions such as cardiovascular diseases, epilepsy and other neurological disorders.
 
An accomplished business leader, Saia has focused her 40-year career building leading global brands in the consumer products and medical technology businesses, including Novartis, Unilever, Revlon and Procter & Gamble. Previously Saia was global head of Vision Care of Alcon and CEO/President of CIBAVision, a Novartis Company. She also previously served on the Board of Directors of Coca-Cola Enterprises.
 
“Throughout my career, I’ve worked with technologically driven companies dedicated to developing new solutions that significantly improve the health and well-being of consumers, and this is where I hope to have an impact at Outset,” said Saia. “There appears to be a serious lack of new and better treatment options for those with kidney disease. This is the sizable opportunity gap I see Outset Medical’s home dialysis solution, Tablo, filling with its pioneering technology that improves outcomes and reduces the cost and complexity of care.”
 
Outset Medical also announced that Ali Osman, senior vice president at Mubadala Investment Company, has stepped off the board.
 
“Ali has been a valuable member of our board as we’ve scaled the company’s growth over the last year,” added Trigg. “His manufacturing and technology operations expertise have advanced our success and we are grateful for his involvement.”